Search

Your search keyword '"Puigvert F."' showing total 10 results
Start Over Author "Puigvert F."
10 results on '"Puigvert F."'

4. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease

Author

Cambray S., Bermudez-Lopez M., Bozic M., Valdivielso J.M., Castro E., María V., Molí T., Vidal T., Soria M., Aladrén Regidor Ma.J., Almirall J., Ponz E., Arteaga Coloma J., Bajo Rubio Ma.A., Belart Rodríguez M., Gascón A., Bover Sanjuan J., Puigvert F., Bronsoms Artero J., Cabezuelo Romero J.B., Muray Cases S., Calviño Varela J., Caro Acevedo P., Carreras Bassa J., Cases Amenós A., Massó Jiménez E., Moreno López R., Cigarrán Guldris S., López Prieto S., Comas Mongay L., Comerma I., Compte Jové Ma.T., Cuberes Izquierdo M., de Álvaro F., Hevia Ojanguren C., de Arriba de la Fuente G., del Pino y Pino Ma.D., Diaz-Tejeiro Izquierdo R., Hormigos A., Dotori M., Duarte V., Estupiñan Torres S., Fernández Reyes Ma.J., Fernández Rodríguez Ma.L., Fernández G., Galán Serrano A., García Cantón C., García Herrera A.L., García Mena M., Gil Sacaluga L., Aguilar M., Górriz J.L., Huarte Loza E., Lerma J.L., Liebana Cañada A., Marín Álvarez J.P., Martín Alemany N., Martín García J., Martínez Castelao A., Martínez Villaescusa M., Martínez I., Moina Eguren I., Moreno Los Huertos S., Mouzo Mirco R., Munar Vila A., Muñoz Díaz A.B., Navarro González J.F., Nieto J., Carreño A., Novoa Fernández E., Ortiz A., Fernandez B., Paraíso V., Pérez Fontán M., Peris Domingo A., Piñera Haces C., Prados Garrido Ma.D., Prieto Velasco M., Puig Marí C., Rivera Gorrín M., Rubio E., Ruiz P., Salgueira Lazo M., Martínez Puerto A.I., Sánchez Tomero J.A., Sánchez J.E., Sans Lorman R., Saracho R., Sarrias M., Serón D., Soler M.J., Barrios C., Sousa F., Toran D., Tornero Molina F., Usón Carrasco J.J., Valera Cortes I., Vilaprinyo del Perugia Ma.M., Ruiz V., Pallarés V., Altozano C.S., Ródenas M.A., Sanitaria de Arán I.G.G.Á.B., Gil F.A., Criado E.G., Belinchón R.D., Fernández Toro J.Ma., and Antonio J.

Subjects
cardiovascular risk, genetic association, adult, genotype, allele, chronic kidney failure, cohort analysis, major clinical study, Klotho protein, Article, homozygote, aged, cause of death, female, multicenter study, male, priority journal, cardiovascular mortality, single nucleotide polymorphism, follow up, human, prospective study
Abstract

Background. Chronic kidney disease (CKD) is associated with an elevated risk of all-cause mortality, with cardiovascular death being extensively investigated. However, non-cardiovascular mortality represents the biggest percentage, showing an evident increase in recent years. Klotho is a gene highly expressed in the kidney, with a clear influence on lifespan. Low levels of Klotho have been linked to CKD progression and adverse outcomes. Single nucleotide polymorphisms (SNPs) of the Klotho gene have been associated with several diseases, but studies investigating the association of Klotho SNPs with noncardiovascular death in CKD populations are lacking. Methods. The main aim of this study was to assess whether 11 Klotho SNPs were associated with non-cardiovascular death in a subpopulation of the National Observatory of Atherosclerosis in Nephrology (NEFRONA) study (n ¼ 2185 CKD patients). Results. After 48 months of follow-up, 62 cardiovascular deaths and 108 non-cardiovascular deaths were recorded. We identified a high non-cardiovascular death risk combination of SNPs corresponding to individuals carrying the most frequent allele (G) at rs562020, the rare allele (C) at rs2283368 and homozygotes for the rare allele (G) at rs2320762 (rs562020 GG/AG þ rs2283368 CC/CT þ rs2320762 GG). Among the patients with the three SNPs genotyped (n ¼ 1016), 75 (7.4%) showed this combination. Furthermore, 95 (9.3%) patients showed a low-risk combination carrying all the opposite genotypes (rs562020 AA þ rs2283368 TT þ rs2320762 GT/TT). All the other combinations [n ¼ 846 (83.3%)] were considered as normal risk. Using competing risk regression analysis, we confirmed that the proposed combinations are independently associated with a higher fhazard ratio [HR] 3.28 [confidence interval (CI) 1.51-7.12]g and lower [HR 6 × 10-6 (95% CI 3.3 × 10-7-1.1 × 10-5)] risk of suffering a non-cardiovascular death in the CKD population of the NEFRONA cohort compared with patients with the normal-risk combination. Conclusions. Determination of three SNPs of the Klotho gene could help in the prediction of non-cardiovascular death in CKD. © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2020
Full Text
View/download PDF

6. Bladder cancer index : Cross-cultural adaptation into Spanish and psychometric evaluation

Author

Schmidt, Stefanie, Riel, Ricard, Frances, Albert, Lorente Garín, José Antonio, Bonfill, X. (Xavier), Martinez Zapata, María José, Suárez Varela, María Morales, De la Cruz, Javier, Emparanza, José Ignacio, Sánchez, María José, Zamora, Javier, Ramos Goñi, Juan M., Alonso, J, Ferrer Forés, Maria Montserrat, Becerra, Virginia, Pardo Cladellas, Yolanda, Fores, M. F., Garin, O., Villagran, C. O., Suñol, R., Osorio, Dimelza, Cosp, X. B., Canovas, E., Pardo, G. S., Bolívar, I., Bachs, Jordi, Maroto, J. P., Quintana, M. J., Martínez Zapata, M. J., Lorente, C. M., Algaba, Ferran, Redorta, P., Esquena, Salvador., Puigvert, F., Vernooij, R., Martínez, A., Pijoan Zubizarreta, J. I., Martínez, L., Castro Diaz, D. M., Bastida, J. L., Pacheco, A. S., López, C. G., Cozar Olmo, J. M., Martínez, C., Chan, D. C., Sanchez Perez, M. J., Díaz Moratinos, A. I., Luis, A. M., Hervás, A., Ocaña, C. V., Varona, C., Burgos, Javier, Polo Rubio, J. A., López-Fando Lavalle, L., Jimenez Cidre, M. A., Garcia, A. M., Farras, N. P., Lopez, R. M., Garcia, S. S., Abraira, Víctor, Dos Santos, V. G., De la Cámara, A. G., Martinez, J. P., Muñoz, H. G., Cabeza Rodríguez, M. A., Díaz, I. R., Sanz Jaka, J. P., Velásquez, M. J., González, A. L., Morales, M., Camps, Carlos, Díaz, C. C., Vidal, E. M., Ballester, F. S., Juan Escudero, J. U., Peidro, J. P., Torrecilla, J. L., Ramos Campos, M. M., and Cebollada, M. M.

Abstract

Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach's alpha. Construct validity was assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to assess responsiveness. Results: Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53. Conclusions: The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and comprehensive tool for assessing quality of life across a wide range of bladder cancer patients.

Published
2014

7. Abstracts

Author

Gulbis A., Dunham F., Deltenre, M., Burette, A., de Reuck, M., Drabs, Ph., Jonas, C., Izquierdo, F., Marti, J., Zaragozano, R., Pereiro, M., Vicente-Rodríguez, J., Arañô, P., Valdivia, J. G., Romero, F., Rosa, J., Sánchez Santos, J. A., Jiménez-Cruz, J. F., Beamud, A., Boronat, F., Mompo, J. A., Boronat, F., Gallego, J., Alonso, M., Guillén, M., Llopis, B., Jiménez-Cruz, J. F., Vicente-Rodríguez, J., Algaba, F., Valls, F., Martínez, R., Prosper, F., Mareno, B., Fernández, J., Iranzo, S., Alonso, M., Oliver, F., Obaidat, F., Morer, F., Viscasillas, P., Rajmil, H. O., Vicente-Rodríguez, J., Puigvert, F., Ginecología, S., Valdivia, J. G., Elizalde, A., López, J. A., Izquierdo, F., Villarroya, S., Aguiló, R., Moya, J., Morera, R., Saumench, J., Ferrer, G., Alberti, A., Pac, J., Cantó, A., Pac, J., Moya, J., Rivas, J., Wittmoser Raymond, Sastre, V. Font, Casellas, J. Carabias, Sastre, V. Font, Montiel, X. Saura, Alcalde, R. P., Abadal, J., Baños, F., Miró, S., Canueva, A., Vázquez-Iglesias, J. L., Castro, J., Lorenzo, A., Debén, A. G., Rodríguez, J. M., Arnal, F., Pérez Piqueras, J., Moreno Muro, M., Moreno Vara, J., Serrano Martínez, R., Abad Vallejo, J., Gutiérrez Pérez, J. A., Santa Valiente, J. M., Díaz Lobón, J. M., Peñaloza, Arecio, Piña, R., Tulena, E., Garavito, J., Llorens, P., Altschiller, H., Bañados, G., Pisano, R., Goldin, L., Scheinwald, G., Moya, P., Levy, I., Barrios, P., Borrell, J., Barri, J., Piñol, J., Sala, J., Paniagua Estévez M., Jiménez Mesa G., González Lazo N., Menckén, P., Senent, C., Clémente, G., Pérez de Ayala, V., Castellanos, D., Aldequer, M., Torres, J., Rabago, L., Alcalá Santaella, R., Russo, A., Jung, M., Meier, H. J., Mennicken, C., Manegold, B. C., Grá Oramas, B., Casanueva, A., Enríquez, A., Robres, A., Camacho, P., Pistoia, M. A., Amicucci, G., Guadagni, S., Pistoia, F., Resta, V., Paolini, M. R., De Petris, G., Bultrini, F., Pizzuti, G., Clemente, G., Lara, V. G., Calabrese, M., Ranalletta, D., Poscente, A., Massucci, G., Gossetti, F., Durana, J., Arijón, J., Valbuena, L., Forteza, J., Guiteras Val, Jordi, Varas Lorenzo, M. J., Manchón, A., López Moreno, J. L., Alegre, J., Ferrando, J., Reig, G., Moreno, E., García-Conde, J., Rey, J. F., Greff, M., Maupetit, P., Pereira, S., Soto, A., Bordas, J. M., Mondelo, F., Heredia, D., Vilar, J., Fuster, F., Viola, C., Peláez, G., Rodés, J., Van Gossum, M., Delfosse, Jacques, Sommelet, Jean, and Coudane, Henry

Published
1984
Full Text
View/download PDF

10. Is the suckling period and application pattern relevant for fluazuron against tick infestation in cows and their suckling calves?

Author

Suárez G, Robaina D, Muela A, Tatiana S, Puigvert F, Alvariza S, and Pareja L

Subjects
Animals, Cattle, Female, Lactation, Milk, Pregnancy, Tandem Mass Spectrometry veterinary, Cattle Diseases drug therapy, Cattle Diseases parasitology, Phenylurea Compounds administration & dosage, Tick Infestations drug therapy, Tick Infestations veterinary
Abstract

Background: Fluazuron is a chitin synthesis inhibitor administered as a pour-on formulation in cattle for tick control. This study analyzes under endemic tick infestation, the incidence of the pour-on application pattern on the plasma levels of fluazuron in calves and cows in the lactation period of the beef cow. Two hundred and ninety-two beef cows around parturition were treated with a commercial pour-on formulation of fluazuron at a rate of 2.5 mg/kg of body weight. A total of 4 treatments were carried out on days 0, 32, 77, and 117. At each administration time, the cows were grouped according to the pour-on administration pattern: long (~ 60 cm pour-on application surface) and short (~ 30 cm pour-on application surface). Fluazuron levels in cows and calves plasma were determined before the third and fourth application for each subgroup (n = 10) by HPLC-MS/MS. During the entire study, cow-calf pairs were maintained under field conditions and qualitatively examined for tick infestation on the day of each treatment. Both treatments (long and short) schemes were designed to prevent the annual persistence of ticks., Results: No animals with presence of ticks were identified during the first 117 days of the study, except for three cows and one calf at the time of the third application (day 77). There were no differences after 40 days (day 77) post-treatment of the second application (30 ± 5 ppb vs. 28.5 ± 12 ppb, p > 0.05) and 45 days (day 117) after the third application (147 ± 55 ppb vs 140 ± 46 ppb, p > 0.05) between groups of cows treated with the long or short pour-on application, respectively. Plasma concentration of fluazuron at second and third application was increased (3.3 and 2.9 times, respectively) in calves under free suckling compared to cows. Nevertheless, both groups of cows and calves showed a significant increase in plasma concentration of fluazuron between times (4.9 times, p < 0.0001 and 2.8 times, p < 0.0001, respectively). In both groups, tick prevalence was 0% throughout the trial, except for day 77, which reached 1%., Conclusions: The main conclusions of this study were the following: 1) Different administration patterns (long vs. short) did not differ in plasma levels of fluazuron.; 2) Given that only the cows were treated and lactating calves presented higher plasma levels of fluazuron than cows, passage through milk appears to be relevant and possibly due to a cumulative effect and continuous drug intake., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results